Special Issue "CAR-T Cell Therapy-Novel Approaches and Challenges"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (28 February 2019)
Dr. Vita Golubovskaya
1. Research and Business Development, Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA 94806, USA
2. Department of Medicine, University of Oklahoma, Oklahoma City, OK 73126, USA
Website | E-Mail
Interests: Immunotherapy; CAR-T cells; tumor microenvironment; checkpoint protein; hypoxia; tumor survival signaling
CAR (chimeric antigen receptor)-T cell therapy became a highly promising type of cell therapy with two recently FDA-approved CAR-T cell therapy agents: Kymriah (Novartis) and Yescarta (Kite/Gilead). CAR contains single chain variable fragment ScFv of antibody against tumor-associated antigen, followed by a hinge, transmembrane domain, co-activation domain (CD28, 4-1BB, CD27 or other) and activation CD3 zeta domain. Once CAR-T cell binds tumor-associated antigen, it becomes activated and kills target cancer cell. Recent clinical trials on hematological cancers demonstrated big success of this therapy. Unfortunately, in solid cancer there are many challenges exist to overcome for successful therapy such as presence of repressive tumor microenvironment, repressive T regulatory (Treg) cells, physical barriers for CAR-T cells to reach the tumor and other factors. This issue will highlight novel approaches and perspectives of CAR-T cell therapy and also focus on challenges on the road to clinic.Dr. Vita Golubovskaya
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.